EP4205757C0 - Expressionsvektor für 24-hydrolase zur vorbeugung von amyotropher lateralsklerose - Google Patents
Expressionsvektor für 24-hydrolase zur vorbeugung von amyotropher lateralskleroseInfo
- Publication number
- EP4205757C0 EP4205757C0 EP22211222.9A EP22211222A EP4205757C0 EP 4205757 C0 EP4205757 C0 EP 4205757C0 EP 22211222 A EP22211222 A EP 22211222A EP 4205757 C0 EP4205757 C0 EP 4205757C0
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydrolase
- prevention
- expression vector
- lateral sclerosis
- amyotrophic lateral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18306411 | 2018-10-29 | ||
EP19801491.2A EP3873511B1 (de) | 2018-10-29 | 2019-10-28 | Expressionsvektor für cholesterin-24-hydrolase in der therapie von amyotropher lateralsklerose |
PCT/EP2019/079365 WO2020089154A1 (en) | 2018-10-29 | 2019-10-28 | Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19801491.2A Division EP3873511B1 (de) | 2018-10-29 | 2019-10-28 | Expressionsvektor für cholesterin-24-hydrolase in der therapie von amyotropher lateralsklerose |
Publications (3)
Publication Number | Publication Date |
---|---|
EP4205757A1 EP4205757A1 (de) | 2023-07-05 |
EP4205757B1 EP4205757B1 (de) | 2024-12-04 |
EP4205757C0 true EP4205757C0 (de) | 2024-12-04 |
Family
ID=64267745
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19801491.2A Active EP3873511B1 (de) | 2018-10-29 | 2019-10-28 | Expressionsvektor für cholesterin-24-hydrolase in der therapie von amyotropher lateralsklerose |
EP22211222.9A Active EP4205757B1 (de) | 2018-10-29 | 2019-10-28 | Expressionsvektor für 24-hydrolase zur vorbeugung von amyotropher lateralsklerose |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19801491.2A Active EP3873511B1 (de) | 2018-10-29 | 2019-10-28 | Expressionsvektor für cholesterin-24-hydrolase in der therapie von amyotropher lateralsklerose |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220054597A1 (de) |
EP (2) | EP3873511B1 (de) |
JP (2) | JP7515776B2 (de) |
CN (1) | CN112955169B (de) |
AU (1) | AU2019373340A1 (de) |
CA (1) | CA3118163A1 (de) |
ES (1) | ES2936254T3 (de) |
FI (1) | FI3873511T3 (de) |
HU (1) | HUE060949T2 (de) |
WO (1) | WO2020089154A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2944358T3 (es) | 2017-01-30 | 2023-06-20 | Brainvectis | Vector de expresión para la colesterol 24-hidrolasa en terapia de ataxias espinocerebelosas de repetición de poliglutamina |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
AU6248994A (en) | 1993-02-22 | 1994-09-14 | Rockefeller University, The | Production of high titer helper-free retroviruses by transient transfection |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
WO2009034127A1 (en) * | 2007-09-12 | 2009-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of the cyp46a1 gene for the treatment of alzheimer's disease |
JP5937088B2 (ja) * | 2010-10-15 | 2016-06-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ハンチントン病の治療法におけるコレステロール−24−ヒドロラーゼのための発現ベクター |
EP3044318B1 (de) | 2013-09-13 | 2019-05-01 | California Institute of Technology | Selektive rückgewinnung |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
MX2018006840A (es) | 2015-12-11 | 2019-03-28 | California Inst Of Techn | Focalizacion de peptidos para dirigir virus adenoasociados. |
ES2944358T3 (es) * | 2017-01-30 | 2023-06-20 | Brainvectis | Vector de expresión para la colesterol 24-hidrolasa en terapia de ataxias espinocerebelosas de repetición de poliglutamina |
-
2019
- 2019-10-28 JP JP2021523208A patent/JP7515776B2/ja active Active
- 2019-10-28 US US17/289,182 patent/US20220054597A1/en active Pending
- 2019-10-28 CN CN201980072109.7A patent/CN112955169B/zh active Active
- 2019-10-28 EP EP19801491.2A patent/EP3873511B1/de active Active
- 2019-10-28 ES ES19801491T patent/ES2936254T3/es active Active
- 2019-10-28 EP EP22211222.9A patent/EP4205757B1/de active Active
- 2019-10-28 AU AU2019373340A patent/AU2019373340A1/en active Pending
- 2019-10-28 CA CA3118163A patent/CA3118163A1/en active Pending
- 2019-10-28 HU HUE19801491A patent/HUE060949T2/hu unknown
- 2019-10-28 WO PCT/EP2019/079365 patent/WO2020089154A1/en unknown
- 2019-10-28 FI FIEP19801491.2T patent/FI3873511T3/fi active
-
2024
- 2024-06-14 JP JP2024096551A patent/JP2024123093A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019373340A1 (en) | 2021-06-03 |
EP4205757B1 (de) | 2024-12-04 |
EP4205757A1 (de) | 2023-07-05 |
EP3873511B1 (de) | 2022-12-07 |
EP3873511A1 (de) | 2021-09-08 |
WO2020089154A1 (en) | 2020-05-07 |
HUE060949T2 (hu) | 2023-04-28 |
JP7515776B2 (ja) | 2024-07-16 |
CA3118163A1 (en) | 2020-05-07 |
US20220054597A1 (en) | 2022-02-24 |
ES2936254T3 (es) | 2023-03-15 |
CN112955169A (zh) | 2021-06-11 |
CN112955169B (zh) | 2025-03-04 |
JP2022512838A (ja) | 2022-02-07 |
FI3873511T3 (fi) | 2023-01-31 |
JP2024123093A (ja) | 2024-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3902802A4 (de) | Zusammensetzungen zur inhibierung von ubiquitinspezifischer protease 1 | |
HUE061505T2 (hu) | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel | |
EP3692028A4 (de) | Hemmung von ubiquitin-spezifischer peptidase 30 | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
MA46180A (fr) | Analogues de l'amyline | |
EP3364337C0 (de) | Desktriptoren persistenter merkmale für video | |
EP3328429A4 (de) | Peptide und antikörper zur beseitigung von biofilmen | |
EP3695635A4 (de) | Minderung des risikos für freisprechinteraktionen | |
EP3833609A4 (de) | Debonding-system für verschluss | |
IL268688A (en) | Improved use of botulinum neurotoxin in the treatment of sialorrhea | |
EP3631470A4 (de) | Bestimmung des einsetzens von amyotropher lateralsklerose | |
EP3415146A4 (de) | Inhibitor der inflammasomaktivierung | |
EP3728260A4 (de) | Exo-aza-spiro-hemmer der menin-mll-wechselwirkung | |
EP3630078A4 (de) | Chemoembolisationsmittel | |
EP3655036C0 (de) | Zusammensetzungen zur behandlung von stressbedingten störungen | |
MA53924A (fr) | Modulateurs de l'expression d'apol1 | |
EP3464210A4 (de) | Opferschicht für herstellung von elektrochromer vorrichtung | |
EP3619334A4 (de) | Verfahren zur abscheidung von nanoverzwillingten nickel-molybdän-wolfra-mlegierungen | |
EP3634266A4 (de) | System zur entfernung von kotsteinen | |
MA53474A (fr) | Distribution de lingettes | |
IL282311A (en) | Use of reboxetine to treat narcolepsy | |
EP3527868C0 (de) | Molch für rohrleitungen | |
DE112018004164A5 (de) | Verfahren zur Wertbestimmung von Parametern | |
EP3468547A4 (de) | Neuartige benzolsulfonamidzusammensetzungen zur behandlung von bösartigen pleuraergüssen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3873511 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20231218 |
|
17P | Request for examination filed |
Effective date: 20231228 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40097390 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20240226 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20240717 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3873511 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602019063273 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
U01 | Request for unitary effect filed |
Effective date: 20241216 |
|
P04 | Withdrawal of opt-out of the competence of the unified patent court (upc) registered |
Free format text: CASE NUMBER: APP_478/2025 Effective date: 20250106 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20250110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250304 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250305 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250304 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250404 |